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Abstract
Joint destruction and tissue responses determine the outcome of
chronic arthritis. Joint inflammation and damage are often the
dominant clinical presentation. However, in some arthritic diseases,
in particular the spondyloarthritides, joint remodeling is a prominent
feature, with new cartilage and bone formation leading to ankylosis
and contributing to loss of function. A role for bone morphogenetic
proteins in joint remodeling has been demonstrated in the
formation of both enthesophytes and osteophytes. Data from
genetic models support a role for bone morphogenetic protein
signaling in cartilage homeostasis. Finally, this signaling pathway is
likely to play a steering role in the synovium.
Introduction
The classic signs and symptoms of arthritis - rubor, tumor,
calor, dolor et functio laesa - cover a vast world of dynamic
systemic and local processes with complex interactions
between networks at the cellular and molecular levels. Major
advances in our understanding of the pathology of chronic
arthritis and new imaging techniques have highlighted distinct
mechanisms of disease. In the joint, these include the
development and persistence of an inflammatory and immune
reaction, the activation of tissue destructive enzymes and
cells, and the suppression or stimulation of molecular
pathways regulating homeostasis, repair and remodeling
(Figure 1).
Mechanisms of inflammation and auto-immunity have been
studied most extensively, leading to the identification of key
cell populations, such as T cells, B cells and macrophages,
and of important messenger molecules, including cytokines
such as tumor necrosis factor-α (TNFα). As a result,
innovative targeted therapeutic strategies have an
unprecedented effect on both rheumatoid arthritis (RA) and
the spondyloarthritides (SpA). In addition, new immunological
targets are identified at an amazing pace [1].
Two discoveries have recently opened up new paths of
investigation for cartilage and bone destruction: the
molecular characterization of osteoclast differentiation and
activation [2] and the transformation of the synovium into
tissue-destructive pannus tissue [3]. In addition, the success
of the current treatment strategies has prompted new
attention to be focused on repair and remodeling responses
of joint tissues [4].
Tissue responses to inflammation or destruction in the joint
can be physiological or pathological. Normal tissue responses
include the regeneration or repair of soft and hard tissues,
including cartilage and bone. Tissue regeneration involves a
complete restoration of the original tissue with maintenance
of function and homeostasis. This is perceived as a rare
event. In tissue repair, the damaged tissue is replaced by a
surrogate tissue with, at best, a partial restoration of its
function. This is likely less durable and may evolve over time
into functional failure. The articular cartilage has a very limited
tissue restoration and repair capacity [5]. In bone, a tissue
with a remarkable repair potential, such responses appear
suppressed, probably by persistent inflammation [6]. In
addition, abnormal tissue responses leading to joint
remodeling, such as new cartilage and bone formation, may
result in joint ankylosis and further loss of function [7].
We have used these tissue responses as a basis for an
alternative mechanistic classification of chronic arthritis [8].
The disease can be defined as a ‘destructive’ arthritis, a
‘steady-state’ arthritis, and a ‘remodeling’ arthritis. In the first
form, very little, if any, restoration or repair is observed, even
with control of the inflammatory process. In the second form,
local restoration or repair responses may be sufficient for
many years, although ultimately joint homeostasis can be lost,
resulting in joint failure. Finally, remodeling with neocartilage
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and bone formation can be present. This may result in
excessive responses, causing joint ankylosis, thereby directly
contributing to loss of joint function and disability. In this
concept, existing clinical boundaries are of less importance
for the understanding of the molecular processes involved.
More importantly, translation of this concept into animal
models of disease could further strengthen our mechanistic
approach to chronic arthritis.
Bone morphogenetic proteins
Reactivation of molecular signaling pathways that are critical
for tissue formation during development and growth is
increasingly recognized in the homeostasis, repair and
remodeling of postnatal tissues. We have hypothesized that
such signaling pathways including bone morphogenetic
proteins (BMPs) may also be of importance in arthritis [4,8,9].
BMPs and closely related growth and differentiation factors
comprise a large group of structurally related polypeptides
that belong to the transforming growth factor-β (TGFβ)
superfamily [10]. The original discovery of BMPs as protein
factors that ectopically induce a cascade of endochondral
bone formation in vivo [11] has strongly stimulated the study
of their function in skeletal development (for a review, see
[12]) and joint morphogenesis (for a review, see [13]).
However, BMPs are involved in a wide array of biological
processes, both during development and in postnatal life
[14]. These include the specification of the dorso-ventral
body axis and the development, growth and homeostasis of
many organs. BMPs can act as morphogens, growth factors
or cytokines depending on their spatio-temporal expression
and target cells. Their downstream effects include cell
lineage determination, differentiation, motility, adhesion and
death [14].
BMPs induce ligand-dependent type I and type II receptor
heterodimerization. These receptors are transmembrane
serine-threonine kinases and phosphorylate intracellular
receptor-smad signaling molecules (R-smad1/5) that bind
common smad4 (co-smad4) and then translocate to the
nucleus [10]. The diversity of cell responses to BMPs can at
least partially be explained by differences in the affinities of
different ligands for specific type I and II receptor
combinations. BMP signaling is further regulated by extra-
cellular antagonists such as noggin, chordin, gremlin, the
DAN/Cerberus family, follistatin, follistatin-related protein and
sclerostin (for a review, see [15]), by accessory receptors
and by intracellular inhibitors. Transcriptional responses to
BMP signaling are tightly controlled by different co-activators
and co-repressors [10]. BMPs can also activate mitogen
activated kinases such as p38 [16].
Bone morphogenetic proteins in ‘remodeling
arthritis’
Our group has been investigating the role of BMPs in an
animal model of remodeling arthritis [17,18]. Spontaneous
arthritis in aging male DBA/1 mice is characterized by new
cartilage and bone formation at the entheses, progressively
leading to joint ankylosis [19]. The proximal interphalangeal
joints or ankles of the hindpaws are mainly involved. Other
features of the model include dactylitis and nail lesions. We
therefore consider this murine arthritis a model for tissue
remodeling in SpA and, in particular, in psoriatic arthritis [19].
The exact trigger for entheseal new tissue formation is not
clear. Injury, mechanical stress, hormones and activation of
the immune system may all play a role [19-21]. Joint
remodeling in this model is characterized by accumulation of
spindle-shaped fibroblast-like cells, chondrogenic differentia-
Figure 1
The signs and symptoms of arthritis are caused by distinct processes in the joint. Synovitis with extensive inflammation is characteristic. Formation
of pannus tissue and activation of osteoclasts contributes to joint destruction. Tissue remodeling is characterized by new cartilage and bone
formation eventually leading to ankylosis. The images presented were obtained from mice with methylated bovine serum albumin-induced arthritis
(inflammation and destruction) and from mice with spontaneous ankylosing enthesitis (remodeling).Page 3 of 7
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tion, chondrocyte hypertrophy and replacement of the carti-
lage by bone. This is a typical cascade of endochondral bone
formation. However, in continuity with the endochondral bone
front, a small zone of direct bone formation is also recognized.
We studied the presence of different BMPs in this process
[17]. BMP2 was associated with early events whereas BMP7
and BMP6 were mainly found in pre-hypertrophic and
hypertrophic chondrocytes, respectively. Overexpression of
noggin, a non-specific endogenous BMP antagonist, inhibited
both clinical onset and severity of disease in a preventive and
therapeutic strategy [17]. Detailed histomorphological
analysis revealed that BMP signaling is critically important in
the early stages of the disease processes, in particular in the
commitment of progenitor cells to the chondrogenic lineage.
Phosphorylation of smad1/5 molecules was used as a marker
for activation of the BMP signaling pathway. Active BMP
signaling was found in cells entering chondrogenic
differentiation. These data were further corroborated by
immunohistochemistry for phosphorylated smad molecules
on human biopsies from entheseal lesions at the achilles
tendon insertion of SpA patients [17].
However, the role of BMP signaling in the cascade of
endochondral bone formation as seen in this model is more
complex. Endogenous expression of noggin is important to
counteract the BMP signal once the cells start chondro-
genesis to allow progression towards chondrocyte hyper-
trophy and new bone formation [18]. Therefore, in noggin
haploinsufficient mice, where endogenous noggin levels are
reduced by about 50%, incidence of disease is not different
from the wild type but progression of disease is delayed [18].
As for all animal models of disease, this model has both
strengths and weaknesses. It allows the molecular analysis of
ankylosis originating from the entheseal sites. However, the
role of inflammation, innate and adaptive immunity in the
murine disease is not yet clear and the specific relevance
thereof for human SpA remains to be defined.
BMP and related TGFβ signaling have also been studied in
osteophyte formation in mouse models of osteoarthritis (OA).
Injection of recombinant BMP2 into healthy murine knees
enhanced proteoglycan synthesis in the articular cartilage but
also stimulated osteophyte formation. Interestingly, osteo-
phytes induced by BMP2 injection were found predominantly
in the regions where the growth plate met the joint space,
whereas TGFβ-induced osteophytes originated from zones of
the periosteum that were more remote from the growth plate
[22,23]. Synovial macrophages appear to be critical in this
process as osteophyte formation induced by TGFβ was
reduced after depletion of macrophages by intra-articular
liposomes. The number of BMP2 and BMP4 positive cells in
these experiments declined upon deletion of the macro-
phages [24]. Similarly, depletion of macrophages also inhibited
osteophyte formation in collagenase-induced arthritis, a mouse
model of joint instability leading to osteoarthritis [25]. Papain-
induced arthritis is a mouse model in which direct injection of
papain depletes articular cartilage proteoglycans, leading to
accelerated osteoarthritis-like lesions. Osteophyte formation
in this model can be inhibited by adenoviral overexpression of
both BMP and TGFβ antagonists. Again, expression of BMP2
and BMP4 in this model was markedly increased in the
synovium [26]. Further analysis in this model and in a
spontaneous model of osteoarthritis suggested that BMP2
expression occurs at later stages than TGFβ3 [27].
Two groups have studied expression of BMPs in human
osteophytes [28,29]. Zoricic and colleagues [28] observed
three different types of bone formation in the growing
osteophyte: endochondral, and membranous from the periost
and from the endosteum. Immunohistochemistry demon-
strated BMP2 in both fibrous matrix and osteoblasts. BMP3
was found in osteoblasts and osteoclasts, BMP6 in osteo-
cytes and osteoclasts, and BMP7 in hypertrophic chondro-
cytes, osteoblasts and osteocytes. Nakase and colleagues
[29] demonstrated BMP2 in fibroblastic mesenchymal cells,
fibrochondrocytes, chondrocytes and osteoblasts at both the
mRNA and protein levels.
A key question is whether remodeling in SpA and OA are
different (Figure 2). The enthesis has been suggested as the
primary site of disease in SpA [30]. New tissue formation at
the enthesis is a factor that contributes to pathology in SpA.
The exact nature of the process is controversial. A classic
point of view suggests that the formation of enthesophytes is
a repair phenomenon [31]. However, the tissue response is
excessive, suggesting that the process contributes more to
pathology than to restoration of tissue function.
Osteophyte formation as typically seen in osteoarthritis may
be of a different nature. It does not arise from the insertion
sites but at the junctional zone where the synovium overlies
the bone [32] (Figure 2). There is no evidence that the
osteophyte contributes to the signs and symptoms in
peripheral joints. Rather, it is hypothesized that osteophytes
represent an attempt at repair and a stabilizing effort in a
damaged joint [33]. Ankylosis is rarely, if ever, seen.
Therefore, the nature of osteophytes in OA and
enthesophytes in SpA is very different. Enthesophyte
formation in SpA is a potential therapeutic target, in particular
since new tissue formation and inflammation appear to be at
least partially uncoupled events [34].
Bone morphogenetic proteins in
‘steady-state’ arthritis
The articular cartilage is a highly specialized tissue with
unique properties. Its function is critically dependent on the
interaction between the cells (chondrocytes) and their extra-
cellular matrix and it is resistant to vascular invasion and
mineralization. The complex regulation of extracellular matrix
synthesis suggests that the articular chondrocytes can retain
Available online http://arthritis-research.com/content/9/2/207cartilage homeostasis to a certain degree or for a limited
period in case of chronic or progressive strain such as seen
in OA. This homeostasis is critically dependent on the
balance between, and the magnitude of, anabolic and
catabolic molecular pathways. However, the restoration and
repair capacity of the articular chondrocytes is limited [5].
Chondral lesions without injury to the subchondral bone do
not heal spontaneously and gradually worsen. Osteochondral
defects penetrate into the bone and show some attempts at
repair, with invasion of mesenchymal progenitor cells from the
subchondral bone marrow cavities. However, fibrocartil-
aginous rather than articular cartilage tissue is formed.
The role of BMPs in articular cartilage homeostasis and repair
has been extensively studied in vitro and ex vivo (for a review,
see [8]). More recently, the positive or anabolic effects of
BMPs in this context have been further corroborated by in
vivo data [18,35] (Table 1). Rountree and colleagues [35]
developed a conditional gene deletion system that takes
advantage of the expression of Gdf5, the murine homolog of
cartilage derived morphogenetic protein-1 in the joint inter-
zone during morphogenesis. Heterozygous BMP-receptor
(Bmpr)-Ia+/- mice, engineered to express a Cre recombinase
in the Gdf5 locus (Gdf5Cre/Cre;BmprIa+/-) were crossed with
mice that carry a floxed BmprIa allele (Gdf5+/+;BmprIafloxP/floxP).
The  Gdf5+/Cre;BmprIa-/floxP conditional knockout progeny
were viable and showed some mild developmental defects
(short ears, soft tissue syndactyly between digit 1 and 2 and
tarsal joint ankylosis). Importantly, Gdf5+/Cre;BmprIa-/floxP mice
failed postnatally to maintain articular cartilage in many joints
compared to litter mate ‘control’ (Gdf5+/Cre;BmprIa+/floxP)
mice. At birth the digit joints appeared normal, with high
expression of both aggrecan and collagen type II mRNA in
the two groups. As soon as one week after birth and more
clearly by two weeks, changes in the articular cartilage had
occurred. Expression of proteoglycans and collagen type II
was greatly reduced. In other joints of forefeet and hindfeet
similar changes were observed at seven weeks. By nine
months of age, many regions of the cartilage were severely
damaged. Progressive degenerative changes were also
observed in the knee joints and triggered a loss of function.
Our group studied the effect of noggin (Nog) haplo-
insufficiency on joint destruction in two different models of
arthritis, collagen-induced arthritis and methylated bovine
serum albumin (mBSA) induced arthritis [18]. Noggin is
expressed in articular cartilage. Reduction of noggin levels by
about 50% (haploinsufficient Nog+/LacZ mice) did not affect
severity of inflammation in both models. However, reduced
noggin levels in Nog+/LacZ mice protected the articular
cartilage in mBSA arthritis (Table 1). This was associated
with enhanced BMP signaling in the articular cartilage as
demonstrated by immunohistochemistry for phosphorylated
smad1/5. Overexpression of noggin in wild-type mice in both
models increased cartilage damage, probably by reducing
BMP activity [18].
Intra-articular injections of BMP2 in the mouse knee have
been used to assess the effect of this BMP on articular
cartilage in vivo. BMP2 stimulates proteoglycan synthesis in
normal knees but cannot do this in a model of destructive
arthritis [36].
Bone morphogenetic proteins in joint
destruction
The role of BMPs in the normal and inflamed synovium, in
particular in a destructive arthritis such as RA, is less clear.
The increasing interest in mesenchymal populations in the
synovium and the role of stem cells in arthritis [37-39] has
stimulated research into embryonic signaling pathways that
typically guide mesenchymal stem cell behavior [4,40]
(Table 2). We have demonstrated that BMP2 and BMP6 are
expressed in synovial biopsies obtained from patients with
chronic arthritis [9]. Protein levels of BMP2 and BMP6 were
significantly higher in patients with RA and SpA compared to
non-inflammatory controls. BMP2 and BMP6 protein was
found in both macrophages and fibroblast-like synoviocytes
as demonstrated by immunohistochemistry [9]. BMP2 and
BMP6 expression in fibroblast-like synoviocytes in vitro was
Arthritis Research & Therapy    Vol 9 No 2 Lories and Luyten
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Figure 2
Enthesophytes and osteophytes are different. (a) The enthesophyte
originates from the insertion of capsule and tendons (arrows). The
chondrosynovial border of the articular cartilage is not involved
(asterisks). (b) Osteophyte originating from the border of the articular
cartilage (asterisks). In contrast, the enthesis is normal (arrows).
Table 1
In vivo evidence supporting a role for BMPs in cartilage
homeostasis
Pro-homeostatic effects  Normal BMP receptor type Ia [35]
Noggin haploinsufficiency [18]
Injection of BMP2 [22]
Anti-homeostatic effects Noggin overexpression [18]
BMP, bone morphogenetic protein.upregulated by pro-inflammatory cytokines such as IL1 and
TNFα. We also demonstrated that BMP2 is associated with
fibroblast-like synoviocyte apoptosis in vitro and in vivo [9]. In
contrast,  BMP4 and  BMP5 were downregulated at the
mRNA level in RA and OA samples versus normal controls as
demonstrated by Bramlage and colleagues [41]. In normal
synovium, BMP4 and BMP5 positive cells were found mainly
in the lining layer, whereas in RA these cells were more
scattered.
It is noteworthy that the presence of BMPs in the synovium is
not associated with local cartilage or bone formation at these
sites. This again highlights the complex biology of BMPs that
should be considered as pleiotropic cytokines and growth
factors with distinct effects on different cell types.
Identification of target cells for BMP signaling in synovium
and their biological relevance is, therefore, an important
challenge. Our preliminary observations suggest that both
blood vessel associated cells and mesenchymal cells in the
synovium can be activated by BMPs (unpublished obser-
vations). Expression of different BMP receptors is present in
fibroblast-like synoviocyte cultures [42]. Again, the local
balance with antagonists and the processing of pro-peptides
into mature forms will ultimately determine the impact of BMP
signaling at the single cell and tissue level.
Further evidence may again come from animal models. BMP-
RIa positive cells have been identified as potential mesen-
chymal stem cells in both RA [38] and joints from mice with
collagen-induced arthritis, a model of RA [39]. Surprisingly,
infiltration of cells into the synovium from the bone marrow
apparently precedes the onset of symptoms in the induced
model and a specific role for this cell population in disease
pathogenesis has been hypothesized [39].
Of particular interest are recent data on the epitheloid
character of the lining layer and its transformation towards a
more typical mesenchymal cell type in arthritis [43]. RA
synovial fluid stimulated this so-called epithelial-mesenchymal
transition of normal fibroblast-like synoviocytes, an effect that
could be inhibited in vitro by BMP7.
All these data provide further evidence that BMPs may act as
regulatory molecules within the healthy and inflamed
synovium (Table 2).
Perspectives
There is accumulating evidence that the tissue-resident cells
of the normal synovium are critically involved in chronic
arthritis [44]. These cells include both the mesenchymal
fibroblast-like cells, macrophages and endothelial cells. Little
is known about the role of these cell populations in joint
remodeling - some of them may be targets for BMP signaling.
Different hypotheses have been formulated to explain the role
of such populations in arthritis.
The ‘transformation hypothesis’ proposes that fibroblast-like
synoviocyte are stably transformed by the chronic inflam-
matory processes in the synovium. This results in a more
aggressive cell type, pannocytes, with distinct morphological
characteristics and the ability to attach to and invade the
articular cartilage, as elegantly demonstrated in in vivo
models of cartilage and synoviocyte co-implantation in SCID
mice [45]. Mutations in tumor suppressor genes such as that
encoding p53 have been documented and could explain
some aspect of this altered cell behavior [46]. An alternative
view suggests that low activity fibroblast-like synoviocyte/
mesenchymal stem cells from the sublining zone acquire
phenotypical characteristics of lining layer cells but lack
positional information with overgrowth and invasion of
cartilage and bone [47].
The transformation hypothesis was incorporated in the
‘effector cell hypothesis’. The late destructive phase of RA,
typically characterized by pannus formation, osteoclast
activation and secretion of tissue-destructive enzymes, is
considered mainly T-cell independent as it seems to be driven
by an ‘autonomous’ fibroblast-like synoviocyte population, as
suggested by the transformation hypothesis. Expansion and
influx of mesenchymal cell populations are considered as a
contributing factor in these processes [48].
These two hypotheses clearly focus on the tissue-destructive
aspect of arthritis. There is also increasing evidence that the
tissue-resident cell populations (mesenchymal cells, macro-
phages and endothelial cells) and embryonic signaling path-
ways play a part in the initiation and progression of arthritis.
The ‘stromal code’ hypothesis [49] states that the stromal cell
population of an organ provides differentiation, retention and
exit signals for immune cells. The endothelium defines a
stromal address code regulating cell entry by a number of
selectins, integrins and chemokines. The code within the
tissue further steers behavior of cells that have invaded the
synovium.
Based on these theories and new experimental evidence from
both developmental biology and arthritis research, we have
proposed the ‘signaling center hypothesis’ [37]. Inflammation
Available online http://arthritis-research.com/content/9/2/207
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Table 2
BMP signaling in synovitis
Ex vivo human biopsies Increased expression of BMP2 and 
BMP6 [9]
Decreased expression of BMP4 and 
BMP5 [41]
Presence of BMP receptor Ia positive 
cells in RA [38]
Animal model data Influx of BMP receptor Ia positive 
cells precedes onset of arthritis [39]
BMP, bone morphogenetic protein; RA, rheumatoid arthritis.and tissue destruction trigger a reaction aimed at repairing
and conserving tissue function. However, in some cases this
process is ill-coordinated within an inflammatory environment
and leads to changes in the tissue-resident cell populations.
Mesenchymal cells accumulate either by local proliferation,
transdifferentiation or influx from other compartments such as
blood or bone marrow. These cell populations can typically
form signaling centers that regulate the behavior of
surrounding cells. This concept from developmental biology
places the stromal code hypothesis in a broader biological
context. It enables understanding of not only the destructive
but also the remodeling processes as the molecular signaling
centers can guide both, dependent on the balance between
tissue-destructive and homeostatic/reparative molecular
signaling. As summarized above, there is increasing evidence
that BMPs are involved in these processes. Moreover,
interactions between mesenchymal cells and immune cells
are likely to be critical in this process and may contribute to
the differences between destructive and remodeling arthritis.
In this context it is noteworthy that we and others identified
macrophages as a source of BMPs in the joint [9,24].
Conclusion
BMPs are pleiotropic cytokines, growth factors and
morphogens. Increasing evidence supports a critical role for
BMP signaling in joint remodeling, particularly in entheso-
phyte formation in SpA. In addition, BMPs support cartilage
homeostasis and repair. The role of BMP signaling in
synovitis is still unclear, but a role as regulatory molecules is
hypothesized.
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